[Transition from intravenous to subcutaneous prostacyclin in pulmonary hypertension].
Treatment of arterial pulmonary hypertension with epoprostenol (intravenous prostacyclin) improves survival and quality of life, but the need for an implanted central venous catheter is associated with frequent complications, that often (as in the case of infection or dislodgment) are serious and require catheter replacement. Treprostinil is a prostacyclin analogue suitable for continuous subcutaneous administration. We report the successful transition from intravenous epoprostenol to subcutaneuos treprostinil in four patients with severe pulmonary hypertension who suffered from serious complications associated with the epoprostenol infusion system.
Escribano Subías
Pilar
P
Servicio de Cardiología. Unidad de Hipertensión Pulmonar, Insuficiencia Cardíaca y Trasplante Cardíaco. Hospital Universitario 12 de Octubre. Madrid. España. med022585@saludalia.com
Cea-Calvo
Luis
L
Tello de Menesses
Rocío
R
Gómez Sánchez
Miguel A
MA
Delgado Jiménez
Juan F
JF
Sáenz de la Calzada
Carlos
C
D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001424:Bacterial Infections / Q000209:etiology / Q000517:prevention & control; D002405:Catheterization, Central Venous / Q000009:adverse effects; D011464:Epoprostenol / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D007262:Infusions, Intravenous / Q000009:adverse effects; D007279:Injections, Subcutaneous; D008875:Middle Aged
D000959:Antihypertensive Agents; D011464:Epoprostenol; C427248:treprostinil